Stress Reduction Intervention for Women With Ischemic Heart Disease

NCT ID: NCT02893579

Last Updated: 2018-07-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-06

Study Completion Date

2018-07-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single center, randomized controlled trial which will include women with ischemic heart disease to receive either a self-directed stress reduction program delivered through a smart-phone application or activity tracking only for the first month ("early SR intervention" and "delayed SR intervention", respectively). Patients will be monitored for 1 month for application use and step counts via telephone or email interview and/or collection of screen-captured data. Baseline questionnaires will be repeated at the end of one month to assess for all primary and secondary measures, at which time the control group (activity tracking only) will be introduced to the intervention program. The early SR intervention group will not receive a new intervention but will be encouraged to continue using the app. Data will be collected for an additional 2 months with all participants in both groups. After the three-month study period, the study will close with the collection of final questionnaire data.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Early Intervention

Stress reduction intervention 1 time a month

Group Type EXPERIMENTAL

Early SR intervention

Intervention Type BEHAVIORAL

Self-directed stress reduction program delivered through a smart-phone application

Delayed Intervention

Wait list Control

Group Type EXPERIMENTAL

Delayed SR intervention

Intervention Type BEHAVIORAL

Activity tracking only for the first month

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Early SR intervention

Self-directed stress reduction program delivered through a smart-phone application

Intervention Type BEHAVIORAL

Delayed SR intervention

Activity tracking only for the first month

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Presence of ischemic heart disease as defined by one or more of the following within the last 2 years:
* Positive stress test
* Admission for ACS, PCI, or CABG
* Typical or atypical ischemic symptoms within one month of enrollment
* On stable dose of anti-anginal medications for at least 2 months
* Able and willing to provide informed consent and comply with all aspects of the protocol
* Owns a smartphone with the ability to download applications for stress reduction and activity tracking
* English-speaking (apps are not available in other languages)

Exclusion Criteria

* Planned for revascularization during the study period
* Self-reported or chart-reviewed diagnosis of psychotic disorder including schizophrenia or schizoaffective disorder, bipolar disorder
* Current participation in a cardiac rehab program or planned participation during the study period
Minimum Eligible Age

21 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

NYU Langone Health

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Harmony Reynolds, MD

Role: PRINCIPAL_INVESTIGATOR

New York University Medical School

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

New York University School of Medicine

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

15-00650

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.